The Richest Woman in the World: How Gina Rinehart Earns her Billions
Why Dell Will Never Be Great Again
There is good news surfacing for pharmaceutical firm AstraZeneca (NYSE: AZN) this morning. Turns out a new drug produced by AZN helps reduce heart patients' chances of dying by more than 20% when compared to the standard treatment. The drug is designed to prevent blood clots in heart patients. The study followed 18,624 patients from 2006 to 2008, with roughly half taking rival medicine Plavix and the other half taking AZN's Brilinta. The results show that patients taking Brilinta had a 4.5% chance of dying, compared to a 5.9% chance for patients on Plavix.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
